EcoR1 Capital’s Aclaris Therapeutics ACRS Stock Holding History

EcoR1 Capital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,509,812	Closed	-$9.77M	–	72
2020 Q4	$9.77M	Sell	1,509,812 -21,500	-1%	-$90.7K	0.53%	29
2020 Q3	$3.94M	Hold	1,531,312	–	–	0.28%	34
2020 Q2	$2.48M	Sell	1,531,312 -556,000	-27%	-$745K	0.18%	39
2020 Q1	$2.17M	Hold	2,087,312	–	–	0.23%	39
2019 Q4	$3.94M	Buy	+2,087,312	New	+$3.46M	0.36%	38
2019 Q1	–	Sell	-613,728	Closed	-$4.54M	–	42
2018 Q4	$4.54M	Buy	+613,728	New	+$6.33M	0.45%	42
2017 Q4	–	Sell	-60,000	Closed	-$1.55M	–	31
2017 Q3	$1.55M	Sell	60,000 -125,472	-68%	-$3.36M	0.21%	34
2017 Q2	$5.03M	Sell	185,472 -487,628	-72%	-$13.3M	0.89%	19
2017 Q1	$20.1M	Buy	673,100 +259,100	+63%	+$7.47M	5.07%	8
2016 Q4	$11.2M	Buy	+414,000	New	+$10.6M	3.58%	11

Other funds holding ACRS

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

EcoR1 Capital's ACRS Position: Q1 2021 in Review

EcoR1 Capital sold out of Aclaris Therapeutics (ACRS) in Q1 2021, closing a stake of 1,509,812 shares — an estimated $9.77M sold.

EcoR1 Capital first reported a position in ACRS in Q4 2016 and held it in 10 quarters. The position peaked at $20.1M in Q1 2017. 97 funds tracked by Wall St. Rank hold ACRS as of Q1 2021.

EcoR1 Capital reported no remaining Aclaris Therapeutics position as of Q1 2021 after selling out during the quarter.
EcoR1 Capital sold 1,509,812 Aclaris Therapeutics shares in Q1 2021, an estimated $9.77M.
EcoR1 Capital first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 10 quarters.
EcoR1 Capital's Aclaris Therapeutics position peaked at $20.1M in Q1 2017.
97 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2021.

Based on EcoR1 Capital's 13F filing for Q1 2021, filed 17 May 2021.